Skip to main content
. 2022 Sep 13;10(9):e005424. doi: 10.1136/jitc-2022-005424

Figure 3.

Figure 3

(A) Immune response and objective clinical response. (B) Landmark analysis of overall survival by complete/partial response (CR/PR) by week 13. (C) Landmark analysis of overall survival by twofold T cell responses by week 13. Ab, antibody; PD-1, programmed death 1.